Four experts presented compelling studies, including two new agents that may expand the potential of KRAS inhibition in lung cancer.

Updates from the world of antibody-drug conjugates included a new therapeutic approach to treatment-resistant ovarian cancer.

This update on sophisticated immunotherapeutic strategies included a special emphasis on their application for solid tumors.

The results of four recent phase I and II immunotherapy trials included the evaluation of a new monoclonal antibody that can improve immune checkpoint inhibitor treatment.